Ali Urman On The Significance Of Upcoming JNJ Covid-19 Vaccine

Ark Invest analyst Ali Urman compares Covid-19 vaccines from John and Johnson, Pfizer, and Moderna and others. She says Johnson and Johnson said that we will likely see data by the end of January with their earnings call coming up and it may come up there. There is also a 50 percent threshold for the efficacy for the vaccine and Ali is hoping for a 80 to 95 percent efficacy.

ON AIR
7:00 am
Market Overtime
replay

Get Market Minute

Daily insights for every investor

FOLLOW US

Ali Urman On The Significance Of Upcoming JNJ Covid-19 Vaccine

Ark Invest analyst Ali Urman compares Covid-19 vaccines from John and Johnson, Pfizer, and Moderna and others. She says Johnson and Johnson said that we will likely see data by the end of January with their earnings call coming up and it may come up there. There is also a 50 percent threshold for the efficacy for the vaccine and Ali is hoping for a 80 to 95 percent efficacy.

ON AIR
7:00 am
Market Overtime
replay

Get Market Minute

Daily insights for every investor

FOLLOW US